Medicine and Health

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

H. Kim, S. Jung, et al.

Discover the promising results of combining Regorafenib and nivolumab in treating unresectable hepatocellular carcinoma. This phase 2 trial led by Hyung-Don Kim and colleagues reveals an objective response rate of 31% and highlights significant immune response changes in long-term responders. A must-listen for anyone interested in innovative cancer therapies!... show more

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

R. J. Kelly, B. V. Landon, et al.

Medicine and Health

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

P. G. M. D. Gooyer, Y. L. Verschoor, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Medicine and Health

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

M. Yarchoan, E. J. Gane, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny